

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2004/052250

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12Q1/18

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FENARD DAVID ET AL: "Secreted phospholipases A2, a new class of HIV inhibitors that block virus entry into host cells" JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 104, no. 5, September 1999 (1999-09), pages 611-618, XP002178980 ISSN: 0021-9738 page 613, column 1, line 2 - line 5 page 615, column 1, last paragraph - column 2, line 1, paragraph 1 figure 2	1-8, 10, 11, 13, 14
Y	----- -/-	1-14

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

17 December 2004

Date of mailing of the international search report

04/01/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Weber, P

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/052250

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	OJWANG J O ET AL: "T30177, AN OLIGONUCLEOTIDE STABILIZED BY AN INTRAMOLECULAR GUANOSINE OCTET, IS A POTENT INHIBITOR OF LABORATORY STRAINS AND CLINICAL ISOLATES OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 39, no. 11, November 1995 (1995-11), pages 2426-2435, XP000946679 ISSN: 0066-4804 page 2427, column 2, paragraph 4 page 2431, column 1, last paragraph - column 2, paragraph 1 figure 5	1-9
Y	-----	1-14
X	NAKASHIMA H ET AL: "ANTI-HUMAN IMMUNODEFICIENCY VIRUS ACTIVITY OF A NOVEL SYNTHETIC PEPTIDE, T22 ('TYR-5,12-LYS-7!POLYPHEMUSIN II): A POSSIBLE INHIBITOR OF VIRUS-CELL FUSION" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 36, no. 6, June 1992 (1992-06), pages 1249-1255, XP009022884 ISSN: 0066-4804 page 1251, column 1, paragraph 2 page 1252, column 2, last paragraph - page 1253, column 2, paragraph 1 figure 7	1-8
Y	-----	1-14
X	PANNECOUQUE CHRISTOPHE ET AL: "New class of HIV integrase inhibitors that block viral replication in cell culture" CURRENT BIOLOGY, vol. 12, no. 14, 23 July 2002 (2002-07-23), pages 1169-1177, XP002271109 ISSN: 0960-9822 page 1171, column 2, last paragraph - page 1172, column 1, last paragraph page 1175, column 2, paragraph 4 figure 2	1-7, 10, 13, 14
Y	----- -/--	1-14

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2004/052250

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>LIN PIN-FANG ET AL: "A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 16 SEP 2003, vol. 100, no. 19, 16 September 2003 (2003-09-16), pages 11013-11018, XP002271110 ISSN: 0027-8424 page 11013, column 2, last paragraph page 11015, column 1, paragraph 3 figure 1</p>	1-7,10, 13,14
Y	-----	1-14
X	<p>PAUWELS R ET AL: "Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives." NATURE. ENGLAND 1 FEB 1990, vol. 343, no. 6257, 1 February 1990 (1990-02-01), pages 470-474, XP002271145 ISSN: 0028-0836 figure 2</p>	1-6,9, 10,13,14
Y	-----	1-14
Y	<p>SPENLEHAUER CATHERINE ET AL: "A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1" VIROLOGY, vol. 280, no. 2, 15 February 2001 (2001-02-15), pages 292-300, XP002271111 ISSN: 0042-6822 page 296, column 1, last paragraph - column 2, paragraph 1 page 297, column 1, paragraph 2 page 297, column 2, paragraph 2 page 298, column 2, paragraph 2 figures 3,4</p>	10,11, 13,14
Y	<p>EP 1 335 019 A (TAKEDA CHEMICAL INDUSTRIES LTD) 13 August 2003 (2003-08-13) paragraph '0001! examples 2,3 figures 4,5</p>	10,11, 13,14
	----- -/--	

BEST AVAILABLE COPY

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/052250

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>RICHMAN LARRY ET AL: "An adenovirus-based fluorescent reporter vector to identify and isolate HIV-infected cells" JOURNAL OF VIROLOGICAL METHODS, vol. 99, no. 1-2, January 2002 (2002-01), pages 9-21, XP002271112 ISSN: 0166-0934 abstract page 19, column 2, paragraph 2</p>	10,11, 13,14
Y	<p>LEE AH ET AL: "Generation of the replication-competent human immunodeficiency virus type 1 which expresses a jellyfish green fluorescent protein" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 233, no. 1, 7 April 1997 (1997-04-07), pages 288-292, XP002142659 ISSN: 0006-291X abstract page 291, column 1, last paragraph figure 4</p>	12-14
X	<p>ANONYMOUS: "Staccato Cell Station™ - Assay" INTERNET ARTICLE, 'Online! February 2003 (2003-02), pages 1-2, XP002271113 Retrieved from the Internet: URL:http://www.calipertech.com/pdf/Staccato_Rapid_Plate_Cell_Station_Assay.pdf&gt; 'retrieved on 2004-02-20! the whole document</p>	15-19
X	<p>ANONYMOUS: "Automation of Cell-Based Assays" INTERNET ARTICLE, 'Online! April 2003 (2003-04), pages 1-4, XP002271114 Retrieved from the Internet: URL:http://www.hudsoncontrol.com/files/ab105b_cellassay_automation.pdf&gt; 'retrieved on 2004-02-20! the whole document</p>	15-19

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2004/052250

### Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 24  
because they relate to subject matter not required to be searched by this Authority, namely:  
Article 52 (4) EPC - Method for treatment of the human or animal body by therapy
2. ☒ Claims Nos.: 20-24  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Claims Nos.: 24

Article 52 (4) EPC - Method for treatment of the human or animal body by therapy

Continuation of Box II.2

Claims Nos.: 20-24

Present claims 20-24 relate to compounds defined by reference to a desirable characteristic, namely "being identifiable with a claimed assay".

The claims cover all compounds having this characteristic, whereas the application provides no support at all within the meaning of Article 6 PCT and no disclosure within the meaning of Article 5 PCT for such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has not been carried out for those claims.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

EST  
ADVANCE  
SEARCH

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/052250

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1335019	A	13-08-2003	AU 1430702 A	27-05-2002
			EP 1335019 A1	13-08-2003
			US 2004043380 A1	04-03-2004
			WO 0240648 A1	23-05-2002
			JP 2002345457 A	03-12-2002

1335019 A1